3 answers
It's not quite a yes-or-no safety question yet - CRISPR works in lab and animal trials, but human trials for inherited diseases are still pretty early, so we don't have long-term safety data on real patients to say definitively either way. The biggest unknowns right now are off-target edits and whether the changes stay stable over decades, but for certain blood disorders and eye diseases the early results look genuinely promising rather than risky.
The real concern isn't whether CRISPR itself works - it does in controlled settings - but whether we can reliably deliver it to the right cells in a living body and whether off-target edits (cuts in unintended spots in the genome) will cause problems down the road. A few trials for blood disorders are underway now, and early results look promising, but you're right that we won't know the full safety picture for years.
CRISPR itself is pretty solid in controlled conditions, but the bigger blind spot people gloss over is what happens when you edit one gene and it cascades into unexpected problems downstream - the human body's systems are so interconnected that fixing one thing sometimes breaks something else you didn't anticipate. We're basically still in the phase where we can do it, but we can't always predict all the consequences, especially years down the line.
Your answer
Log into answer.